INmune Bio Inc. Common stock (INMB) is a publicly traded Healthcare sector company. As of August 26, 2026, INMB trades at $2.40 with a market cap of $65.50M and a P/E ratio of -1.28. INMB moved -1.40% today. Year to date, INMB is +57.79%; over the trailing twelve months it is +8.48%. Its 52-week range spans $1.09 to $11.64. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces INMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for INMB, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $2.40 |
| Market Cap | $65.50M |
| P/E Ratio | -1.28 |
| EPS | $-1.86 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.64 |
| 52-Week Low | $1.09 |
| Volume | 3.54K |
| Avg Volume | 0 |
| Revenue (TTM) | $50.00K |
| Net Income | $-45.93M |
| Gross Margin | 0.00% |
1 analysts cover INMB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.